Panel Backs Drug for Treatment of Gehrig’s Disease
- Share via
ROCKVILLE, Md. — A scientific panel recommended Monday that the government approve the first drug to show any effectiveness against Lou Gehrig’s disease.
The scientists voted, 5 to 4, for the recommendation to the Food and Drug Administration after reviewing tests that suggested a slightly longer survival time for some patients--but no cure for the fatal neuromuscular disease.
The drug, riluzole, appears to help some people live an extra three months, and more than a dozen patients tearfully told the FDA panel that was vital.
“Will it cure me? No,” said Donald Simons, a retired Navy physicist who was diagnosed with the disease in January. “Will it make my life better? I don’t know, but I can hope.”
“I’m in a race against time,” a sobbing Stacey Henninger of Philadelphia told the panel.
There is no approved treatment for amyotrophic lateral sclerosis, or ALS. Victims’ life expectancy--just three to five years--has changed little since the disease killed New York Yankees’ first baseman Lou Gehrig in 1941.
Sign up for Essential California
The most important California stories and recommendations in your inbox every morning.
You may occasionally receive promotional content from the Los Angeles Times.
More From the Los Angeles Times
Podcasts
John Orr was a renowned fire investigator who was also a prolific arsonist, and whose thinly veiled novel helped to convict him. In this episode we hear from the fire captain who first suspected him—and from Orr himself.
Madison McGhee is joined by legendary Dateline host Josh Mankiewicz and esteemed L.A. Times Reporter Richard Winton as the three of them dive into all-things Menendez Brothers, the good, the bad, and the still unknown.
NPR climate editor Sadie Babits talks about why the media has long overlooked the climate crisis, and how that’s starting to change.
